Close Banner
Section Free  - Video Lectures

10. Treatment Optimization for Tic Disorders

Published on April 1, 2023 Certification expiration date: April 1, 2026

David R. Rosenberg, M.D.

Chair of the Department of Psychiatry & Behavioral Neuroscience - Wayne State University School of Medicine

Key Points

  • Treatment of comorbid psychiatric conditions may take precedence in the treatment of tic disorders.
  • Adjustments in medication dosing must consider the waxing and waning nature of tics.
  • There are very limited data regarding long-term treatment of tic disorders.
  • Current guidelines recommend dose reduction on an annual basis if tics are stable.

Free Downloads for Offline Access

  • Free Download Presentation File (PPTX)
  • Free Download Video (MP4)
  • Free Download Audio File (MP3)

Slides and Transcript

Slide 1 of 28

Treatment optimization for tic disorders.

Slide 2 of 28

The selection of a particular treatment approach has to be carefully assessed for each individual case taking into account a number of factors—tic symptom severity, the level of functional impairment, severity of comorbid medical and psychiatric conditions, the child's age at presentation.
References:
  • Murphy, T. K., Lewin, A. B., Storch, E. A., & Stock, S. (2013). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 52(12), 1341-1359.
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 3 of 28

The duration of illness, adequacy and efficacy of other treatment strategies, tolerability of single or combined treatments.
References:
  • Murphy, T. K., Lewin, A. B., Storch, E. A., & Stock, S. (2013). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 52(12), 1341-1359.
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.

Slide 4 of 28

And when establishing the treatment hierarchy, one should begin with the most impairing condition and that may not be the tic.
References:
  • Murphy, T. K., Lewin, A. B., Storch, E. A., & Stock, S. (2013). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 52(12), 1341-1359.
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 5 of 28

Treatment optimization for tic disorders. If the comorbid disorder has a more significant impact on overall quality of life than the tic symptoms, the treatment of comorbid psychiatric conditions such as ADHD, OCD, anxiety disorders, or mood disorders may in fact take precedence.
References:
  • Murphy, T. K., Lewin, A. B., Storch, E. A., & Stock, S. (2013). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 52(12), 1341-1359.
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.

Slide 6 of 28

Once baseline characteristics of tic severity and functional impairment have been established, a collaborative approach towards choosing the appropriate treatment modality needs to be undertaken with the patient and family to determine the necessity and intensity of intervention needed.
References:
  • Murphy, T. K., Lewin, A. B., Storch, E. A., & Stock, S. (2013). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 52(12), 1341-1359.
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 7 of 28

Remember that many patients with tic disorders don't need any treatment at all. Reassurance is sufficient.
References:
  • Murphy, T. K., Lewin, A. B., Storch, E. A., & Stock, S. (2013). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 52(12), 1341-1359.
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.

Slide 8 of 28

Behavior therapy treatment optimization. A standard course of behavior therapy is usually between seven to 14 sessions. That being said, the required number of sessions will vary depending on number of bothersome tics and the patient's parents' ability to master and implement the behavioral strategies.
References:
  • Murphy, T. K., Lewin, A. B., Storch, E. A., & Stock, S. (2013). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 52(12), 1341-1359.
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 9 of 28

Compliance with out-of-session homework and between-session practice assignments including practicing behavioral strategies, making modifications to school and practicing talking about tics, these are all very important aspects of treatment that can impact therapeutic outcome and should be emphasized to patients and their families early during treatment.
References:
  • Murphy, T. K., Lewin, A. B., Storch, E. A., & Stock, S. (2013). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 52(12), 1341-1359.
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.

Slide 10 of 28

Pharmacotherapy. Pharmacologic treatment for tic disorders should be considered only when behavioral interventions fail or aren't available, that is a lack of access, you can't find a therapist who's trained in treating tics, patient factors such as cognitions, willingness to participate or when patients exhibit severe violent tics that need treatment.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
  • Ueda, K., & Black, K. J. (2021). A comprehensive review of tic disorders in children. Journal of Clinical Medicine, 10(11), 2479.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 11 of 28

Before starting treatment with medication, clinicians need to explain the purpose, set a realistic goal to reduce the severity and frequency of tics to the extent that they no longer bother the patient or cause significant problems.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
  • Ueda, K., & Black, K. J. (2021). A comprehensive review of tic disorders in children. Journal of Clinical Medicine, 10(11), 2479.

Slide 12 of 28

The selection of a particular pharmacologic treatment for tics requires a cautious analysis of the risks, benefits including consideration of medication side effect profile, potential interactions with concomitant medications, and comorbidity.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
  • Ueda, K., & Black, K. J. (2021). A comprehensive review of tic disorders in children. Journal of Clinical Medicine, 10(11), 2479.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 13 of 28

Additional factors have to be considered. Those are cost, the insurance coverage, the ease of administration, leveraging side effects such as sedation or areas where you can treat co-occurring problems.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
  • Ueda, K., & Black, K. J. (2021). A comprehensive review of tic disorders in children. Journal of Clinical Medicine, 10(11), 2479.

Slide 14 of 28

Using clonidine or guanfacine for tics with comorbid ADHD. Taking advantage of sedating side effects to administer it nighttime for youth who have trouble falling asleep. Using topiramate for youth with comorbid migraine, excessive sweating, or obesity. These are all critical considerations.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
  • Ueda, K., & Black, K. J. (2021). A comprehensive review of tic disorders in children. Journal of Clinical Medicine, 10(11), 2479.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 15 of 28

The patient age, weight, metabolic factors and medical comorbidity, liver, kidney or other concurrent medical disease also are critically important.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
  • Ueda, K., & Black, K. J. (2021). A comprehensive review of tic disorders in children. Journal of Clinical Medicine, 10(11), 2479.

Slide 16 of 28

Adverse effects often lead to discontinuation of treatment or treatment adherence which can be poor limiting the opportunity to reach optimal dose and response. And here is where the doctor-patient relationship is so critical because if your patient and the family aren't telling you about side effects or concerns and they're not taking the medication regularly that can impact response or lack thereof.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
  • Ueda, K., & Black, K. J. (2021). A comprehensive review of tic disorders in children. Journal of Clinical Medicine, 10(11), 2479.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 17 of 28

Asking patients about common and rare but serious adverse effects at each follow-up assessment provides an opportunity to monitor the issue.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
  • Ueda, K., & Black, K. J. (2021). A comprehensive review of tic disorders in children. Journal of Clinical Medicine, 10(11), 2479.

Slide 18 of 28

And as a rule, medicines are started on a low dose with gradual titration until an effective dose is reached. Adjustments in medication dosing must also take into account the waxing and waning nature of tics so that inadvertent escalation of medication dosage doesn't occur unless truly warranted. Considerable harm happens when a medicine is increased too rapidly because there's concern that there's not enough benefit. All too often, I've seen more good medicines ruined by escalating the dose too rapidly. In children and adolescents, you can't go wrong if you start low, go slow, possibly end up high but give the child or adolescent time to become tolerant to the medicine.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
  • Ueda, K., & Black, K. J. (2021). A comprehensive review of tic disorders in children. Journal of Clinical Medicine, 10(11), 2479.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 19 of 28

Physicians should discuss weaning patients off medicines once symptoms subside so that tics are no longer disruptive.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.

Slide 20 of 28

Discontinuing the medicine. There are many guidelines for the management of tic disorders over the short term. The problem is recommendations for long-term medication management are lacking. Current guidance suggests that dose reduction should be considered on an annual basis if tics are stable. And when considering a discontinuation trial, effort should be made to optimize chances of success by pairing the trial with a period with low tic-inducing social environmental factors, minimal life stressors, and regular and adequate amounts of sleep.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 21 of 28

Encouraging the patient to focus on the importance of their resilience and their strength rather than on tics being a defining factor of their identity is also incredibly helpful for decreasing the salience of residual and lingering tics. So we're empowering our patient, the children, and of course their parents.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.

Slide 22 of 28

Treatment resistance. A number of patients respond only partially to treatment and will continue to experience some degree of tic-related impairment and distress.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 23 of 28

For those patients who fail to respond to initial treatment, it's critical to conduct a thorough assessment and reassessment, solicit feedback from the youth and their families to identify issues which may be preventing treatment response and determine whether any aspects of treatment should be re-emphasized, revisited. Should the diagnosis be revisited? Are they accurate? Are they complete?
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.23

Slide 24 of 28

Children who are unable to engage with HRT or CBIT can benefit from alternative aspects of behavioral therapy and particularly utilizing function-based assessment and intervention related to triggers and consequences for tics may provide additional therapeutic benefits.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 25 of 28

Clinicians also need to focus on areas that can improve overall quality of life even if they don't directly decrease tic frequency or impact tic severity as well as patient adherence to behavioral intervention and compliance with medicine. You can have the best medicine in the world but if your patient isn't taking the medicine it's not going to help. And similarly with a behavioral intervention, if your patient isn't motivated or the family isn't motivated to do the behavioral interventions, they can't work if they're not attempted.
References:
  • McGuire, J. F., Murphy, T. K., Piacentini, J., & Storch, E. A. (2018). The clinician’s guide to treatment and management of youth with Tourette syndrome and tic disorders. Academic Press.

Slide 26 of 28

Key points. Treatment of comorbid psychiatric conditions such as ADHD, OCD, non-OCD anxiety, mood disorders not uncommonly take precedence in treatment of tic disorders, especially if the comorbid disorder has a more significant impact on overall quality of life than the tic symptoms. Adjustments in medication dosing must take the waxing and waning nature of tics into consideration to avoid unnecessary escalation of medication dosage especially if it's not warranted.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 27 of 28

And there are very limited data regarding long-term treatment of tic disorders with current guidelines recommending that dose reduction be considered on an annual basis if the tics are stable.

Slide 28 of 28

Free Files
Success!
Check your inbox, we sent you all the materials there.

Learning Objectives:

After completing this activity, the learner will be able to:

  1. Perform a thorough evaluation of tic disorders in children and adolescents.
  2. Identify evidence-based treatments for children with tic disorders and determine the most suitable for each patient.
  3. Apply appropriate pharmacologic strategies to optimize outcomes for children with tic disorders.

Original Release Date: April 1, 2023

Review and Re-release Date: March 1, 2024

Expiration Date: April 1, 2026

Expert: David Rosenberg, M.D.

Medical Editor: Paz Badía, M.D.

Relevant Financial Disclosures: 

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

  1. View the required educational content provided on this course page.

  2. Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.

  3. Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Free Files
Success!
Check your inbox, we sent you all the materials there.
Continue in the website
Instant access modal

Become a Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Member.

2025–26 Psychopharmacology CME Program

Unlock up to 155 CME Credits, including 40 SA CME Credits.